AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Feb 2023 02:01 PM
RNS
Director/PDMR Shareholding
13 Feb 2023 02:00 PM
RNS
Director/PDMR Shareholding
09 Feb 2023 07:00 AM
RNS
Final Results
01 Feb 2023 03:00 PM
RNS
Total Voting Rights
26 Jan 2023 06:15 PM
RNS
Update on Evusheld US EUA
16 Jan 2023 07:00 AM
RNS
Acquisition of Neogene Therapeutics completed
11 Jan 2023 01:00 PM
RNS
Airsupra (PT027) approved in US for asthma
09 Jan 2023 07:00 AM
RNS
AstraZeneca acquire CinCor for cardiorenal asset
03 Jan 2023 03:00 PM
RNS
Total Voting Rights
30 Dec 2022 11:00 AM
RNS
Director/PDMR Shareholding
28 Dec 2022 07:05 AM
RNS
Calquence Japan approval for treatment-naïve CLL
28 Dec 2022 07:00 AM
RNS
Imfinzi, Imjudo approved in Japan for 3 cancers
21 Dec 2022 07:05 AM
RNS
Lynparza approved in EU for prostate cancer
21 Dec 2022 07:00 AM
RNS
Imfinzi approved in EU for biliary tract cancer
19 Dec 2022 07:20 AM
RNS
Enhertu recommended for EU approval in HER2-low BC
19 Dec 2022 07:15 AM
RNS
Enhertu approved in EU for gastric cancer
19 Dec 2022 07:10 AM
RNS
Imfinzi + Imjudo recommended for approvals in EU
19 Dec 2022 07:05 AM
RNS
Update on Imfinzi PEARL trial
19 Dec 2022 07:00 AM
RNS
Forxiga CHMP opinion for symptomatic chronic HF
15 Dec 2022 07:00 AM
RNS
Update on US review of Lynparza PROpel sNDA
08 Dec 2022 01:30 PM
RNS
Capivasertib PFS in HR-positive breast cancer
01 Dec 2022 03:00 PM
RNS
Block listing Interim Review
01 Dec 2022 03:00 PM
RNS
Total Voting Rights
30 Nov 2022 07:05 AM
RNS
AstraZeneca announces sale of West Chester site
29 Nov 2022 07:00 AM
RNS
AstraZeneca to acquire Neogene Therapeutics
23 Nov 2022 03:30 PM
RNS
Director/PDMR Shareholding
14 Nov 2022 07:10 AM
RNS
Enhertu recommended for EU approval in gastric
14 Nov 2022 07:05 AM
RNS
Imfinzi recommended for approval in the EU for BTC
14 Nov 2022 07:00 AM
RNS
Lynparza combo recommended in the EU for mCRPC
11 Nov 2022 07:00 AM
RNS
Imfinzi + Imjudo approved in US for lung cancer
10 Nov 2022 07:00 AM
RNS
YTD and Q3 2022 Results
09 Nov 2022 07:00 AM
RNS
FDA Advisory Committee recommends PT027 in asthma
04 Nov 2022 07:00 AM
RNS
Beyfortus (nirsevimab) approved in EU
01 Nov 2022 03:00 PM
RNS
Total Voting Rights
26 Oct 2022 07:00 AM
RNS
Capivasertib Phase III trial met primary endpoints
25 Oct 2022 07:00 AM
RNS
Update on MESSINA Phase III trial
24 Oct 2022 07:00 AM
RNS
Imfinzi + Imjudo approved in advanced liver cancer
03 Oct 2022 03:00 PM
RNS
Total Voting Rights
30 Sep 2022 10:30 AM
RNS
Board Committee Changes
27 Sep 2022 07:05 AM
RNS
Koselugo approved in Japan for NF1
27 Sep 2022 07:00 AM
RNS
Tezspire approved in Japan for severe asthma
23 Sep 2022 07:00 AM
RNS
Ultomiris approved in EU for gMG
22 Sep 2022 07:00 AM
RNS
Lynparza approved in China for ovarian cancer
21 Sep 2022 07:00 AM
RNS
Tezspire approved in the EU for severe asthma
20 Sep 2022 07:00 AM
RNS
Evusheld approved in EU for COVID-19 treatment
16 Sep 2022 07:10 AM
RNS
Danicopan Phase III trial met primary endpoint
16 Sep 2022 07:05 AM
RNS
Evusheld positive CHMP opinion in EU
16 Sep 2022 07:00 AM
RNS
Nirsevimab recommended for approval in EU by CHMP
05 Sep 2022 07:05 AM
RNS
Forxiga approved in China for CKD
05 Sep 2022 07:00 AM
RNS
Imfinzi approved in US for biliary tract cancer

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings